|
Number of patients, N
|
16
|
13
|
10
|
6
|
|
Females (%)
|
11 (69)
|
9 (69)
|
7 (70)
|
3 (50)
|
|
Median duration of prior CAN therapy at baseline, years (min; max)
|
1.0 (0; 4)
|
1.0 (0; 4)
|
1.0 (0; 4)
|
1.5 (0; 2)
|
|
Number (%*) of patients in disease remission (physician assessment)
|
9 (60.0)
|
9 (81.8)
|
7 (77.8)
|
4 (80.0)
|
|
Physician Global Assessment, percentage of absent/mild-moderate/severe rating
|
40 / 53 / 0
|
82 / 9 / 0
|
44 / 44 / 11
|
80 / 20 / 0
|
|
Patient assessment of current disease activity; 0–10, median (min; max)
|
1.5 (0; 5)
|
1.0 (0; 4)
|
1.0 (0; 6)
|
0.0 (0; 3)
|
|
Patient assessment of current fatigue; 0–10, median (min; max)
|
2.0 (0; 8)
|
1.0 (0; 7)
|
2,5 (0; 8)
|
4.0 (0; 7)
|
|
Number (%*) of patients without impairment of social life by the disease
|
4 (50)
|
5 (63)
|
2 (33)
|
3 (60)
|
|
CRP, SAA median (mg/dl)
|
0.1/0.5
|
0.1/0.4
|
0.1/0.4)
|
0.0/0.3
|
